Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02322138 · ClinicalTrials.gov registry record · NA
Gastrointestinal Tolerance of Infant Formula
A NA study of Gastrointestinal Tolerance, sponsored by Abbott Nutrition.
- Completed
- Registry status
- NA
- Development phase
- 131
- Enrollment target
- 10
- Study locations
NCT02322138: Completed NA study of Gastrointestinal Tolerance, sponsored by Abbott Nutrition.
NCT02322138 is a NA study of Gastrointestinal Tolerance that has completed, run by Abbott Nutrition. The registered enrollment target is 131 participants, below the 175-participant average among 4 other Gastrointestinal Tolerance trials with a reported enrollment target (25% lower). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02322138, a NA study of Gastrointestinal Tolerance, has completed, sponsored by Abbott Nutrition.
- COMPLETED
- Registry status
- NA
- Development phase
- 131 participants
- Enrollment target
- 10
- Study locations
Study Summary
The study objective is to evaluate the gastrointestinal tolerance of infant formula supplemented with prebiotics.
Primary Outcome
Questionnaire
Conditions Studied
Interventions
- OTHER Experimental 1 Infant Formula
- OTHER Experimental 2 Infant Formula
- OTHER Reference Group
Study Locations (10)
Ohio
- Institute of Clinical Research - Mayfield Heights
- The Cleveland Pediatric Research Center, LLC - Middleburg Heights
Arizona
- W.O.M.B Watching Over Mothers and Babies - Tucson
Colorado
- Clinical Research Advantage/Colorado Springs Health Partners - Colorado Springs
Connecticut
- Norwich Pediatric Group, PC - Norwich
Florida
- SCORE Physician Alliance, LLC - St. Petersburg
Kentucky
- Michael W. Simon, M.D., PSC - Nicholasville
Nebraska
- Women's Clinic of Lincoln, PC. - Lincoln
North Carolina
- White Oak Family Physicians DBA Asheboro Research Associates - Asheboro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2015-01 |
| Est. Completion | 2015-06 |
| Phase | NA |
What the finished NCT02322138 record still lists
NCT02322138 is an interventional study that assigns participants to a tested intervention. The registered 131 participants enrollment target is mid-sized for trials with a published cap, below the 175-participant average among 4 other Gastrointestinal Tolerance trials with a reported enrollment target (25% lower).
The record links to 1 condition, with Gastrointestinal Tolerance appearing as the primary indexed condition, and to 3 interventions - of which Experimental 1 Infant Formula is the first listed.
NCT02322138 lists 10 locations in 9 states (Ohio, Arizona, Colorado).
Frequently Asked Questions
What is clinical trial NCT02322138 about?
NCT02322138 is a clinical study titled "Gastrointestinal Tolerance of Infant Formula". The study objective is to evaluate the gastrointestinal tolerance of infant formula supplemented with prebiotics.
What is the current status of trial NCT02322138?
This trial is currently completed. It is a NA study. The enrollment target is 131 participants. The study started on 2015-01. Estimated completion is 2015-06.
What conditions does trial NCT02322138 study?
This clinical trial studies the following conditions: Gastrointestinal Tolerance.
What interventions are being tested in trial NCT02322138?
The interventions under investigation include: Experimental 1 Infant Formula (OTHER), Experimental 2 Infant Formula (OTHER), Reference Group (OTHER).
Who is sponsoring clinical trial NCT02322138?
This trial is sponsored by Abbott Nutrition, which has 89 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02322138 being conducted?
This trial has 10 study locations across Arizona, Colorado, Connecticut, Florida, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastrointestinal Tolerance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03051464 · 131 participants · Phase 2
No Surgery Trial / Two Dose-escalation Strategies
- NCT04301843 · 131 participants · Phase 2
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
- NCT04748549 · 131 participants · NA
Intraoperative VR for Older Patients Undergoing TKA
- NCT05951179 · 131 participants · Phase 2
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia